FDA Puts Cancer Risk Predictors into Safer Class II Category
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting cancer risk assessment systems into a safer, more controlled category called Class II. This means these devices will have special rules to make sure they work well and keep patients safe. This change helps people get better access to new, helpful tools without unnecessary delays or costs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Cancer Risk Tests Moved to Safer Category
The FDA is placing cancer predisposition risk assessment systems into Class II (special controls). The Agency says this classification provides a reasonable assurance of safety and effectiveness and will enhance patient access by reducing regulatory burdens for these devices.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-16034, Medical Devices; Immunology and Microbiology Devices; Classification of A Multiplex Respiratory Panel To Detect and Identify Emerging Respiratory Pathogen(s) and Common Respiratory Pathogens in Human Clinical Specimens
The FDA is officially classifying a new multiplex respiratory panel as a Class II device, meaning it has special safety rules to follow. This device helps doctors quickly spot both common and new respiratory germs in patient samples. This change makes it safer and easier for patients to get access to these helpful tests without extra delays or costs.
Next: 2025-16036, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Menopause Test System
The FDA is officially putting menopause test systems into a special safety group called Class II to make sure they work well and are safe. This change helps companies bring better menopause tests to patients faster and with fewer hoops to jump through. If you make or use these tests, expect smoother rules soon, helping everyone get reliable results without extra costs or delays.